[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350190-105":59,"doc-detail-350190-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","final-efficacy-and-safety-data-from-the-phase-iii-arrow-study-of-pralsetinib-in-patients-with-advanced-ret-fusionpositive-nonsmall-cell-lung-cancer","Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer","","RET fusions occur in 1%–2% of non–small cell lung cancers (NSCLCs). The ARROW study results supported FDA approval of pralsetinib, an oral selective RET inhibitor, for metastatic RET-altered NSCLC and RET fusion–positive thyroid cancers. ARROW was a phase I/II open-label trial; coprimary endpoints were overall response rate (ORR) and safety. At data lock (May 20, 2024), 281 patients initiated pralsetinib. ORR reached 78% in treatment-naive and 63% in prior chemotherapy patients. Median OS was 44.3 and 39.7 months, and grade ≥3 adverse events included anemia, hypertension, and decreased neutrophils. Safety matched prior reports with manageable toxicity and durable responses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/final-efficacy-and-safety-data-from-the-phase-iii-arrow-study-of-pralsetinib-in-patients-with-advanced-ret-fusionpositive-nonsmall-cell-lung-cancer/350190/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/final-efficacy-and-safety-data-from-the-phase-iii-arrow-study-of-pralsetinib-in-patients-with-advanced-ret-fusionpositive-nonsmall-cell-lung-cancer/350190.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary purpose of the ARROW study for pralsetinib?","Question",{"text":112,"@type":113},"ARROW evaluated pralsetinib in adults with advanced RET-altered malignancies, with coprimary endpoints of overall response rate (ORR) and safety.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What were the reported overall response rate (ORR) results?",{"text":117,"@type":113},"ORR was 78% (95% CI, 69 to 86) in treatment-naive patients and 63% (95% CI, 54 to 71) in patients who had received prior platinum-based chemotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety outcomes were most commonly reported?",{"text":121,"@type":113},"Common grade ≥3 treatment-related adverse events included anemia (21%), hypertension (15%), and decreased neutrophils (13%), with three treatment-related deaths reported.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350190,1790178068,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Clinical Trial Updates  \nFinal Efﬁcacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion– Positive Non–Small Cell Lung Cancer  \nBenjamin Besse, MD, PhD1  ; Vivek Subbiah, MD2,3  ; Giuseppe Curigliano, MD, PhD4,5  ; Daniel W. Bowles, MD6  ; Robert C. Doebele, MD, PhD6; Aaron S. Mansﬁeld, MD7  ; Christina S. Baik, MD, MPH8; Gilberto de Lima Lopes, MD, MBA9  ; Luis Paz-Ares, MD, PhD10  ;  \nMatthew H. Taylor, MD11  ; Daniel S.W. Tan, PhD, MBBS, MRCP12 ; Guzman Alonso, MD13; Shirish M. Gadgeel, MD14  ;  \nGregory P. Kalemkerian, MD15  ; Sai-Hong Ignatius Ou, MD, PhD16  ; Anthonie J. van der Wekken, MD, PhD17  ; Carlos R. Becerra, MD18; Makenzi Evangelist, MD19; Frank Griesinger, MD, PhD20; Stephen V. Liu, MD21 ; Yanyan Lou, MD, PhD22  ; Julien Mazires, MD, PhD23  ; Jason M. Melear, MD24  ; Mohit Narang, MD25  ; Ashish Saxena, MD, PhD26; Michael Thomas, MD27,28  ; Sophia Wang, MS29;  \nAmber Thomassen, AGNP-BC, AOCNP29; Dae Ho Lee, MD, PhD30  ; Dong-Wan Kim, MD, PhD31 ; and Justin F. Gainor, MD32   \nDOI [https://doi.org/10.1200/JCO-25-01489](https://doi.org/10.1200/JCO-25-01489)  \nABSTRACT  \nRET fusions appear in 1%-2% of non–small cell lung cancers (NSCLCs) . The results from the ARROW study ([ClinicalTrials.gov](ClinicalTrials.gov) identiﬁer: NCT03037385) supported US Food and Drug Administration approval of pralsetinib, an oral selective RET inhibitor, for metastatic RETaltered NSCLC and RET fusion–positive thyroid cancers. ARROW was a phase I/II open-label study of pralsetinib 400 mg once daily in RET fusion–positive NSCLCs. Coprimary end points were overall response rate (ORR) and safety. Key secondary end points included duration of response, progression-free survival, and overall survival (OS). At data lock (May 20, 2024), 281 patients initiated pralsetinib (median treatment duration, 15.0 months) . ORR (measurable disease patients; n 5 259) was 78%(95% CI, 69 to 86) for treatment-nave patients and 63%(95% CI, 54 to 71) for prior platinum-based chemotherapy patients. Median OS was 44.3 months (95% CI, 30.9 to 53.1), 50.1 months (95% CI, 28.3 to not reached) in treatmentnave patients, and 39.7 months (95% CI, 27.8 to 53.2) in prior platinum patients. Common grade ≥3 treatment-related adverse events were anemia (21%), hypertension (15%), and decreased neutrophils (13%) . Three treatment-related deaths occurred (pneumonia, n 5 2; interstitial lung disease and rhabdomyolysis, n 5 1 each) . Safety was consistent with previous ARROW reports; no hypersensitivity was reported inpatients receiving prior immunotherapies. Pralsetinib produced robust, durable responses with manageable safety in treatment-nave and previously treated patients with RET fusion–positive NSCLCs, conﬁrming previous ﬁndings with longer follow-up.  \nACCOMPANYING CONTENT  \n Appendix  \n Data Sharing Statement  \n Protocol  \nAccepted February 2, 2026 Published March 26, 2026  \nJ Clin Oncol 44:1190-1197 © 2026 by American Society of Clinical Oncology  \nView Online Article  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nRET fusions are targetable alterations in non–small cell lung cancer (NSCLC) .1 Next-generation selective RET inhibitors pralsetinib and selpercatinib have demonstrated superior efﬁcacy and reduced toxicity compared with earlier therapies.1-6  \nPralsetinib, an oral tyrosine kinase inhibitor selectively targeting oncogenic RET fusions and mutations, exhibits activity against V804 gatekeeper mutations, which confer resistance to multikinase inhibitors.7 Interim analyses of the phase I/II registrational ARROW trial ([ClinicalTrials.gov](ClinicalTrials.gov)[ ](ClinicalTrials.gov)[identi](identi)ﬁ[er:](er:) NCT03037385) demonstrated pralsetinib’s tolerability and efﬁcacy at 400 mg once daily, supporting US Food and Drug Administration approval for treatment of metastatic RET fusion–positive NSCLC in adults and metastatic RET fusion–positive thyroid cancer.5,7-9 Herein, ","cbCaijN84wyr4sGV","https://ap.wps.com/l/cbCaijN84wyr4sGV","pdf",1058402,15,"English","# Introduction\n# Materials and Methods\n## Study Design\n# Efficacy and Safety Results\n## Table 1. Baseline Characteristics in RET Fusion–Positive NSCLC","[{\"question\":\"What was the primary purpose of the ARROW study for pralsetinib?\",\"answer\":\"ARROW evaluated pralsetinib in adults with advanced RET-altered malignancies, with coprimary endpoints of overall response rate (ORR) and safety.\"},{\"question\":\"What were the reported overall response rate (ORR) results?\",\"answer\":\"ORR was 78% (95% CI, 69 to 86) in treatment-naive patients and 63% (95% CI, 54 to 71) in patients who had received prior platinum-based chemotherapy.\"},{\"question\":\"What safety outcomes were most commonly reported?\",\"answer\":\"Common grade ≥3 treatment-related adverse events included anemia (21%), hypertension (15%), and decreased neutrophils (13%), with three treatment-related deaths reported.\"}]","Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer | PDF",1790087618,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7581bdc7740ce1be8df1b410a2f84288.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11904dd6686db11ec4c7dc76be77c618.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba11749d141182d6d89eb0a6bc893284.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c97a92e6b9276285d3c5d945995c173.webp",980,1311]